Acalabrutinib
Aggressive B-Cell Non-Hodgkin Lymphoma
Explore 28 assets in Aggressive B-Cell Non-Hodgkin Lymphoma →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Patrick C. Johnson, MD
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05583149CT.gov Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | — | Active Not Recruiting | — | — | — |
NCT03492125CT.gov A Study Of The Selective PKC-β Inhibitor MS- 553 | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Aggressive B-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Acalabrutinib (this asset) | Patrick C. Johnson, MD | P2 | B · 60 |
| Rituximab | Shanghai EpimAb Biotherapeutics Co., Ltd. | P3 | BB |
| Lipegfilgrastim | Teva Branded Pharmaceutical Products R&D, Inc. | P3 | BB |
| (+)-Vincristine | Universität des Saarlandes | P3 | B |
| Pegfilgrastim | Teva Branded Pharmaceutical Products R&D, Inc. | P3 | B |
| Zanubrutinib | Prelude Therapeutics | P2 | B |
| Obinutuzumab | Institute of Hematology & Blood Diseases Hospital, China | P2 | B |
| Oxaliplatin | Shanghai EpimAb Biotherapeutics Co., Ltd. | P2 | B |
| Dexasone | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | P2 | B |
+42 more in the Aggressive B-Cell Non-Hodgkin Lymphoma cohort
Other indications for Acalabrutinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Chronic Lymphocytic Leukemia | — | P4 | BBB · 75 |
| Follicular Lymphoma | — | P2 | BB · 70 |
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Acalabrutinib in Aggressive B-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/acalabrutinib-aggressive-b-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →